

Frank Smithuis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4648050/publications.pdf>

Version: 2024-02-01

62
papers

2,474
citations

279487

23
h-index

205818

48
g-index

69
all docs

69
docs citations

69
times ranked

2839
citing authors

#	ARTICLE	IF	CITATIONS
1	Spread of artemisinin-resistant <i>Plasmodium falciparum</i> in Myanmar: a cross-sectional survey of the K13 molecular marker. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 415-421.	4.6	363
2	Fake artesunate in southeast Asia. <i>Lancet</i> , The, 2001, 357, 1948-1950.	6.3	202
3	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet</i> , The, 2020, 395, 1345-1360.	6.3	182
4	Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated <i>falciparum</i> malaria: an open-label randomised trial. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 673-681.	4.6	168
5	A current perspective on antimicrobial resistance in Southeast Asia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2963-2972.	1.3	139
6	Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in <i>falciparum</i> malaria: an open-label randomised comparison. <i>Lancet</i> , The, 2006, 367, 2075-2085.	6.3	133
7	In Vivo Parasitological Measures of Artemisinin Susceptibility. <i>Journal of Infectious Diseases</i> , 2010, 201, 570-579.	1.9	133
8	Cytomegalovirus Retinitis: The Neglected Disease of the AIDS Pandemic. <i>PLoS Medicine</i> , 2007, 4, e334.	3.9	105
9	The impact of targeted malaria elimination with mass drug administrations on <i>falciparum</i> malaria in Southeast Asia: A cluster randomised trial. <i>PLoS Medicine</i> , 2019, 16, e1002745.	3.9	105
10	In Vivo Assessment of Drug Efficacy against <i>Plasmodium falciparum</i> Malaria: Duration of Follow-Up. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4271-4280.	1.4	95
11	Safety and Efficacy of Dihydroartemisinin-Piperaquine in <i>Falciparum</i> Malaria: A Prospective Multi-Centre Individual Patient Data Analysis. <i>PLoS ONE</i> , 2009, 4, e6358.	1.1	91
12	Effect of point-of-care C-reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: an open-label, randomised, controlled trial. <i>The Lancet Global Health</i> , 2019, 7, e119-e131.	2.9	61
13	Community engagement and the social context of targeted malaria treatment: a qualitative study in Kayin (Karen) State, Myanmar. <i>Malaria Journal</i> , 2017, 16, 75.	0.8	53
14	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. <i>ELife</i> , 2021, 10, .	2.8	53
15	The relationship between the haemoglobin concentration and the haematocrit in <i>Plasmodium falciparum</i> malaria. <i>Malaria Journal</i> , 2008, 7, 149.	0.8	42
16	Malaria elimination in remote communities requires integration of malaria control activities into general health care: an observational study and interrupted time series analysis in Myanmar. <i>BMC Medicine</i> , 2018, 16, 183.	2.3	40
17	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. <i>BMC Medicine</i> , 2015, 13, 66.	2.3	37
18	<i>Plasmodium falciparum</i> : sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 468-472.	0.7	36

#	ARTICLE	IF	CITATIONS
19	Artemisinin resistance in the malaria parasite, <i>Plasmodium falciparum</i> , originates from its initial transcriptional response. <i>Communications Biology</i> , 2022, 5, 274.	2.0	33
20	The risk of <i>Plasmodium vivax</i> parasitaemia after <i>P. falciparum</i> malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. <i>PLoS Medicine</i> , 2020, 17, e1003393.	3.9	32
21	Treatment Outcomes From the Largest Antiretroviral Treatment Program in Myanmar (Burma). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, e53-e62.	0.9	29
22	CMV retinitis screening and treatment in a resource-poor setting: three-year experience from a primary care HIV/AIDS programme in Myanmar. <i>Journal of the International AIDS Society</i> , 2011, 14, 41-41.	1.2	28
23	Effectiveness and safety of 3 and 5-day courses of artemether-lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in an area of emerging artemisinin resistance in Myanmar. <i>Malaria Journal</i> , 2018, 17, 258.	0.8	27
24	Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2004, 98, 182-192.	0.7	24
25	Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of <i>falciparum</i> malaria in Kachin State, North Myanmar. <i>Tropical Medicine and International Health</i> , 2004, 9, 1184-1190.	1.0	22
26	The 20-minute whole blood clotting test (20WBCT) for snakebite coagulopathy: A systematic review and meta-analysis of diagnostic test accuracy. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009657.	1.3	22
27	<i>Plasmodium vivax</i> Relapse Rates Following <i>Plasmodium falciparum</i> Malaria Reflect Previous Transmission Intensity. <i>Journal of Infectious Diseases</i> , 2019, 220, 100-104.	1.9	19
28	Cost effectiveness and resource allocation of <i>Plasmodium falciparum</i> malaria control in Myanmar: a modelling analysis of bed nets and community health workers. <i>Malaria Journal</i> , 2015, 14, 376.	0.8	15
29	Malaria community health workers in Myanmar: a cost analysis. <i>Malaria Journal</i> , 2016, 15, 41.	0.8	14
30	Evaluation of the forum theatre approach for public engagement around antibiotic use in Myanmar. <i>PLoS ONE</i> , 2020, 15, e0235625.	1.1	14
31	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant <i>Plasmodium falciparum</i> distributions in Southeast Asia. <i>International Journal of Health Geographics</i> , 2016, 15, 37.	1.2	13
32	Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 974.	0.7	13
33	Genetic polymorphisms in the circumsporozoite protein of <i>Plasmodium malariae</i> show a geographical bias. <i>Malaria Journal</i> , 2018, 17, 269.	0.8	12
34	Melioidosis in Myanmar. <i>Tropical Medicine and Infectious Disease</i> , 2018, 3, 28.	0.9	12
35	Myanmar <i>Burkholderia pseudomallei</i> strains are genetically diverse and originate from Asia with phylogenetic evidence of reintroductions from neighbouring countries. <i>Scientific Reports</i> , 2020, 10, 16260.	1.6	11
36	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. <i>Wellcome Open Research</i> , 2021, 6, 64.	0.9	11

#	ARTICLE	IF	CITATIONS
37	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 0, 6, 64.	0.9	11
38	Measuring Mosquito-borne Viral Suitability in Myanmar and Implications for Local Zika Virus Transmission. PLOS Currents, 2018, 10, .	1.4	10
39	Genetic diversity of three surface protein genes in Plasmodium malariae from three Asian countries. Malaria Journal, 2018, 17, 24.	0.8	9
40	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1579-1589.	4.6	8
41	Causes of fever in primary care in Southeast Asia and the performance of C-reactive protein in discriminating bacterial from viral pathogens. International Journal of Infectious Diseases, 2020, 96, 334-342.	1.5	8
42	Geographical distribution of Burkholderia pseudomallei in soil in Myanmar. PLoS Neglected Tropical Diseases, 2021, 15, e0009372.	1.3	7
43	Economic considerations support C-reactive protein testing alongside malaria rapid diagnostic tests to guide antimicrobial therapy for patients with febrile illness in settings with low malaria endemicity. Malaria Journal, 2019, 18, 442.	0.8	4
44	Integration of HIV services with primary care in Yangon, Myanmar: a retrospective cohort analysis. HIV Medicine, 2020, 21, 547-556.	1.0	4
45	A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. PLoS Neglected Tropical Diseases, 2020, 14, e0008109.	1.3	4
46	Polymorphic markers for identification of parasite population in Plasmodium malariae. Malaria Journal, 2020, 19, 48.	0.8	3
47	Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. Malaria Journal, 2021, 20, 366.	0.8	3
48	Inter-prescriber variability in the decision to prescribe antibiotics to febrile patients attending primary care in Myanmar. JAC-Antimicrobial Resistance, 2021, 3, dlaa118.	0.9	2
49	Ambulatory induction phase treatment of cryptococcal meningitis in HIV integrated primary care clinics, Yangon, Myanmar. BMC Infectious Diseases, 2021, 21, 375.	1.3	2
50	Enhanced melioidosis surveillance in patients attending four tertiary hospitals in Yangon, Myanmar. Epidemiology and Infection, 2021, 149, 1-23.	1.0	2
51	Genetic analysis of the orthologous crt and mdr1 genes in Plasmodium malariae from Thailand and Myanmar. Malaria Journal, 2020, 19, 315.	0.8	1
52	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal, 2022, 21, 106.	0.8	1
53	Artemisinin resistance in Myanmar – Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 1002-1003.	4.6	0
54	Title is missing!. , 2020, 17, e1003393.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 17, e1003393.		0
56	Title is missing!. , 2020, 17, e1003393.		0
57	Title is missing!. , 2020, 17, e1003393.		0
58	Title is missing!. , 2020, 17, e1003393.		0
59	Title is missing!. , 2020, 14, e0008109.		0
60	Title is missing!. , 2020, 14, e0008109.		0
61	Title is missing!. , 2020, 14, e0008109.		0
62	Title is missing!. , 2020, 14, e0008109.		0